Mucus‐Penetrating Nanoassembly as Potential Oral Phototherapeutic Formulation against Multi‐Drug Resistant Helicobacter pylori Infection
Authors:
Abstract
Helicobacter pylori (H. pylori) infection presents increasing challenges to antibiotic therapies in limited penetration through gastric mucus, multi‐drug resistance (MDR), biofilm formation, and intestinal microflora dysbiosis. To address these problems, herein, a mucus‐penetrating phototherapeutic nanomedicine (RLs@T780TG) against MDR H. pylori infection is engineered. The RLs@T780TG is assembled with a near‐infrared photosensitizer T780T‐Gu and an anionic component rhamnolipids (RLs) for deep mucus penetration and light‐induced anti‐H. pylori performances. With optimized suitable size, hydrophilicity and weak negative surface, the RLs@T780TG can effectively penetrate through the gastric mucus layer and target the inflammatory site. Subsequently, under irradiation, the structure of RLs@T780TG is disrupted and facilitates the T780T‐Gu releasing to target the H. pylori surface and ablate multi‐drug resistant (MDR) H. pylori. In vivo, RLs@T780TG phototherapy exhibits impressive eradication against H. pylori. The gastric lesions are significantly alleviated and intestinal bacteria balance is less affected than antibiotic treatment. Summarily, this work provides a potential nanomedicine design to facilitate in vivo phototherapy in treatment of H. pylori infection.Keywords
Funding Information
- National Natural Science Foundation of China (22207058)
This publication has 34 references indexed in Scilit:
- Oral pH sensitive GNS@ab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiomeNanomedicine: Nanotechnology, Biology and Medicine, 2019
- Helicobacter pylori Biofilm Formation and Its Potential Role in PathogenesisMicrobiology and Molecular Biology Reviews, 2018
- Mucus models to evaluate the diffusion of drugs and particlesAdvanced Drug Delivery Reviews, 2018
- Engineering nanomaterials to overcome the mucosal barrier by modulating surface propertiesAdvanced Drug Delivery Reviews, 2018
- Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialThe Lancet, 2016
- Antibiotic-Induced Changes in the Intestinal Microbiota and DiseaseTrends in Molecular Medicine, 2016
- Effects of Antibiotics on Gut MicrobiotaDigestive Diseases, 2016
- The intestinal microbiota and its role in human health and diseaseThe Journal of Medical Investigation, 2016
- Highly Stable Near-Infrared Fluorescent Organic Nanoparticles with a Large Stokes Shift for Noninvasive Long-Term Cellular ImagingACS Applied Materials & Interfaces, 2015
- Biofilm Formation byHelicobacter pyloriand Its Involvement for Antibiotic ResistanceBioMed Research International, 2015